Exabis Library
Welcome to the e-CCO Library!
P505: Efficacy of MMX-mesalamine monotherapy for maintenance of remission in ulcerative colitis patients after mucosal healing
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P505: Factors influencing outcomes from surgery for Crohn’s disease: A perspective from a district hospital
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P505: Real word long-term efficacy and safety of vedolizumab in managing ulcerative colitis versus crohn's disease: results from “long vedo” italian multicenter study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P505: Real-world short-term effectiveness of ustekinumab in Crohn’s disease: Results from the ENEIDA Registry
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P505: Smoking is associated with the development of adverse events of biological therapy in patients with Inflammatory Bowel Disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P505: The effect of using a question prompt list in outpatient clinic consultations in a Dutch inflammatory bowel disease population
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P506 Increased risk of anti-drug antibodies to a second anti-TNF in patients who developed antibodies to the first anti-TNF
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P506: Endoscopic and clinical outcomes of upadacitinib in patients with moderate to severe Crohn's disease by baseline disease severity
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P506: Incidence risk of colorectal cancer, non-melanoma skin cancers and non-Hodgkin lymphoma in Japanese patients with ulcerative colitis based on large-scale claims database
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P506: Psychological factors and quality of life in inflammatory bowel diseases patients: the Psycho study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P506: Rates of clinical remission among patients with Ulcerative Colitis from real-world clinical practice settings from Germany
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P506: Serum infliximab and antibodies to infliximab levels in Crohn’s disease and ulcerative colitis patients on long-term maintenance therapy
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P506: Steroid treatment for longer than 2 weeks leading to admission predicts higher colectomy rates in children with acute severe ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P506: The Impact of Anxiety in Patients With Inflammatory Bowel Diseases Treated With Biologics during COVID Lockdown. A Comparative Study between Hospitalized and non-hospitalized patients
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P507 Ustekinumab: Medium-term outcomes from a UK multicentre real-world cohort
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P507: Clinical role, optimal timing and frequency of measurement of serum infliximab levels and anti-infliximab antibody titres in patients with inflammatory bowel disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P507: Efficacy of Infliximab after failure of subcutaneous anti-TNF agents in patients with moderate-to-severe ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P507: Need for surgery in patients with ulcerative colitis in the era of biologic therapy.
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P507: Nutrition status in pre-surgical Crohn's disease, active Crohn's disease, Crohn's disease in remission and ulcerative colitis in remission: a cross-sectional study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P507: United States and European patient perspectives on the impact of moderate-to-severe Ulcerative Colitis on sexual activity: Communicating Needs and Features of IBD Experiences (CONFIDE) survey
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM